Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL

被引：24

作者：

Tripodi, Armando ^{[1
,2
]}

Di Iorio, Giancarlo ^{[3
]}

Lippi, Giuseppe ^{[4
]}

Testa, Sophie ^{[5
]}

Manotti, Cesare ^{[6
]}

机构：

[1] Univ Milan, Milan, Italy

[2] IRCCS Ca Granda Maggiore Hosp Fdn, Dept Clin Sci & Community Hlth, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy

[3] Gen Hosp, Anticoagulat Serv, Clin Chem Lab, Pescara, Italy

[4] Acad Hosp, Dept Pathol & Lab Med, Lab Clin Chem & Hematol, Parma, Italy

[5] Gen Hosp, Ctr Thrombosis & Hemostasis, Cremona, Italy

[6] Anticoagulat Serv, Fidenza, Italy

来源：

CLINICAL CHEMISTRY AND LABORATORY MEDICINE | 2012年 / 50卷 / 12期

关键词：

anticoagulation; new oral anticoagulants; thrombosis; warfarin; DIRECT THROMBIN INHIBITOR; COAGULATION ASSAYS; DABIGATRAN ETEXILATE; RIVAROXABAN; REVERSAL; INTERFERENCE;

D O I：

10.1515/cclm-2012-0327

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

At variance with vitamin K antagonists, the new oral anticoagulants (NOAs) can be prescribed at fixed dosage without adjustment by laboratory testing. However, this does not necessarily mean that the laboratory does not play a role for their management. This position paper represents the consensus document of three Italian scientific societies dealing with laboratory issues in thrombosis and hemostasis. It is aimed at reviewing: 1) which test(s) should be used to evaluate the anticoagulant effect of each of the NOAs presently available (i.e., dabigatran, rivaroxaban and apixaban); 2) the patients to be investigated; and 3) the timing of investigation.

引用

页码：2137 / 2140

页数：4

共 25 条

[1] Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].

Ageno, Walter ;

Gallus, Alexander S. ;

Wittkowsky, Ann ;

Crowther, Mark ;

Hylek, Elaine M. ;

Palareti, Gualtiero .

CHEST, 2012, 141 (02) :E44S-E88S

[2] Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay [J].

Barrett, Yu Chen ;

Wang, Zhaoqing ;

Frost, Charles ;

Shenker, Andrew .

THROMBOSIS AND HAEMOSTASIS, 2010, 104 (06) :1263-1271

[3] Impact of dabigatran on a large panel of routine or specific coagulation assays Laboratory recommendations for monitoring of dabigatran etexilate [J].

Douxfils, Jonathan ;

Mullier, Francois ;

Robert, Severine ;

Chatelain, Christian ;

Chatelain, Bernard ;

Dogne, Jean-Michel .

THROMBOSIS AND HAEMOSTASIS, 2012, 107 (05) :985-997

[4] Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects [J].

Eerenberg, Elise S. ;

Kamphuisen, Pieter W. ;

Sijpkens, Meertien K. ;

Meijers, Joost C. ;

Buller, Harry R. ;

Levi, Marcel .

CIRCULATION, 2011, 124 (14) :1573-1579

[5] Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? [J].

Favaloro, Emmanuel J. ;

Lippi, Giuseppe .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (05) :755-757

[6] Laboratory reporting of hemostasis assays: the final post-analytical opportunity to reduce errors of clinical diagnosis in hemostasis? [J].

Favaloro, Emmanuel J. ;

Lippi, Giuseppe .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2010, 48 (03) :309-321

[7] Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests [J].

Halbmayer, Walter-Michael ;

Weigel, Guenter ;

Quehenberger, Peter ;

Tomasits, Josef ;

Haushofer, Alexander C. ;

Aspoeck, Gerold ;

Loacker, Lorin ;

Schnapka-Koepf, Mirjam ;

Goebel, Georg ;

Griesmacher, Andrea .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (09) :1601-1605

[8] Determination of Rivaroxaban in Human Plasma Samples [J].

Harenberg, Job ;

Erdle, Sandra ;

Marx, Svetlana ;

Kraemer, Roland .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2012, 38 (02) :178-184

[9] Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays [J].

Hillarp, A. ;

Baghaei, F. ;

Blixter, I. Fagerberg ;

Gustafsson, K. M. ;

Stigendal, L. ;

Sten-Linder, M. ;

Strandberg, K. ;

Lindahl, T. L. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (01) :133-139

[10] Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors [J].

Kaatz, Scott ;

Kouides, Peter A. ;

Garcia, David A. ;

Spyropolous, Alex C. ;

Crowther, Mark ;

Douketis, Jim D. ;

Chan, Anthony K. C. ;

James, Andra ;

Moll, Stephan ;

Ortel, Thomas L. ;

Van Cott, Elizabeth M. ;

Ansell, Jack .

AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 :S141-S145

← 1 2 3 →